MS-049

Research use only, not for human use.

A potent, selective, and cell-active dual inhibitor of PRMT4 and PRMT6 with IC50 of 34±10 nM and 43±7 nM, respectively.

A potent, selective, and cell-active dual inhibitor of PRMT4 and PRMT6 with IC50 of 34±10 nM and 43±7 nM, respectively; displays >30-fold and >300-fold selectivity over PRMT8 and PRMT1/3, does not inhibits PKMTs, DNMTases, RNA methyltransferases; reduces the H3R2me2a mark in HEK293 cells with IC50 of 0.97 uM.

MS049 (0.1-10 μM; 20 hours) reduces the H3R2me2a mark in HEK293 cells in a concentration dependent manner (IC50=0.97±0.05 μM).MS049 (0.1-100 μM; 72 hours) inhibits endogenous PRMT4 methyltransferase activity in a concentration dependent manner resulting in reduced levels of cellular asymmetric arginine dimethylation of Med12 (Med12-Rme2a, IC50=1.4±0.1 μM) in HEK293 cells.MS049 is selective for PRMT4 and PRMT6 over a broad range of epigenetic modifiers, including other PRMTs, PKMTs, DNMTs, KDMs, and methyllysine/methylarginine reader proteins, and non-epigenetic targets. Western Blot Analysis Cell Line:HEK293 cells Concentration:0.1, 1, 10 μM Incubation Time:20 hours Result:Reduced the H3R2me2a mark in HEK293 cells in a concentration dependent manner (IC50=0.97±0.05 μM).Western Blot Analysis Cell Line:HEK293 cells Concentration:0.1, 1, 10, 100 μM Incubation Time:72 hours Result:Reduced levels of cellular asymmetric arginine dimethylation of Med12 (Med12-Rme2a, IC50=1.4±0.1 μM) in HEK293 cells.

——

MS049

Chromatin/Epigenetic

HMTase

PRMT4|PRMT6

Cancer

——

1502816-23-0

248.3639

C15H24N2O

>98% (HPLC)

DMSO: ≥ 31 mg/mL

CNCCN1CCC(OCC2=CC=CC=C2)CC1

1-Piperidineethanamine, N-methyl-4-(phenylmethoxy)-

(-20℃)

With Ice Pack

≥ 2 years